Category Archives: Transhuman News

PUBLIC RELEASE DATE:

30-Oct-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

Rochelle, NY, October 30, 2014Several companies are developing spacecraft designed to take ordinary citizens, not astronauts, on short trips into space. "Space tourism" and short periods of weightlessness appear to be safe for most individuals according to a series of articles on space biomedicine published in New Space, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The articles are available free on the New Space website until November 30, 2014.

James Vanderploeg, MD, MPH and colleagues, University of Texas Medical Branch, Galveston, coauthored an article outlining the research that has been done to identify the risks and challenges involved in human commercial spaceflight. The authors describe the development of wearable biomedical monitoring equipment for spaceflight participants and of a medical and physiological database. In addition, the suthors also discuss topics such as the risk of electromagnetic interference and ionizing radiation to implanted medical devices in the article "The Human Challenges of Commercial Spaceflight: An Overview of Medical Research Conducted by the University of Texas Medical Branch Through the Federal Aviation Administration Center of Excellence."

"One of the most important areas of New Space research is to determine whether there are biomedical conditions that would disqualify ordinary citizens from a short ride to the edge of space. This first rigorous, peer-reviewed work on a broad range of volunteers indicates most people can take that brief trip," concludes Editor-in-Chief of New Space Prof. Scott Hubbard, Stanford University, in the Editorial "Space Biomedicine -- Who Can Travel to the Final Frontier?"

###

About the Journal

New Space facilitates and supports the efforts of researchers, engineers, analysts, investors, business leaders, and policymakers to capitalize on the opportunities of commercial space ventures. Spanning a broad array of topics including technological advancements, global policies, and innovative applications, the journal brings the new space community together to address the challenges and discover new breakthroughs and trends in this epoch of private and public/private space discovery. The Journal is published quarterly online with Open Access options and in print. Complete table of contents are available on the New Space website.

About the Publisher

More:
Is space tourism safe or do civilians risk health effects?

PUBLIC RELEASE DATE:

30-Oct-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

New Rochelle, NY, October 30, 2014Oligonucleotide-based therapeutics present unique challenges when it comes to testing their potential to cause reproductive and developmental harm. New consensus guidelines for toxicity testing that take into consideration the combined chemical and biological characteristics of these novel biopharmaceuticals are presented in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers. The article is available free on the Nucleic Acid Therapeutics website until November 30, 2014.

Joy Cavagnaro, Access BIO (Boyce, VA), Cindy Berman, Berman Consulting (Wayland, MA), Doug Kornbrust, Preclinisight (Reno, NV), Tacey White, Exponent (Philadelphia, PA), Sarah Campion, Pfizer (Groton, CT), and Scott Henry, Isis Pharmaceuticals (Carlsbad, CA), coauthored the white paper that highlights key points to consider in the design of scientifically valid and predictive toxicity studies. The authors summarize the findings of the Reproductive Subcommittee of the Oligonucleotide Safety Working Group (OSWG) in the article "Considerations for Assessment of Reproductive and Developmental Toxicity of Oligonucleotide-Based Therapeutics."

"I highly commend this latest white paper from the OSWG to researchers and regulators alike involved in the development and implementation of oligonucleotide or antisense based interventions," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.

Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Graham C. Parker, PhD.

###

About the Journal

Nucleic Acid Therapeutics is an authoritative, peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. Nucleic Acid Therapeutics is the official journal of the Oligonucleotide Therapeutics Society. Complete tables of content and a sample issue may be viewed on the Nucleic Acid Therapeutics website.

Here is the original post:
New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs